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BACKGROUND: Patients with glioblastoma have a poor prognosis, with 5-year survival rates <5%. Nivolumab is an IgG4 monoclonal antibody inhibitor of programmed death 1 (PD-1) receptor with demonstrated efficacy in multiple cancer types. In phase 1 cohorts 1c and 1d of CheckMate 143 (NCT02017717), the safety and tolerability of nivolumab with radiotherapy ± temozolomide was evaluated in patients with newly diagnosed glioblastoma. METHODS: Following surgery, patients in cohort 1c received nivolumab 3 mg/kg Q2W with standard radiotherapy and temozolomide concurrently (75 mg/m2 daily), and then with adjuvant temozolomide (150-200 mg/m2 for 5 days/28 days for ≥6 cycles). Cohort 1d patients had unmethylated MGMT and received nivolumab 3 mg/kg Q2W with radiotherapy and no temozolomide. Nivolumab was continued Q2W for patients in both cohorts until progression/unacceptable toxicity. RESULTS: Most patients (61%) in cohorts 1c (n=31) and 1d (n=26) had measurable disease at enrollment. In cohort 1c, 39% and 52% of patients had methylated and unmethylated MGMT promoters, respectively. To date (cutoff, 3/23/2016), treatment has been well tolerated. Treatment discontinuation in cohorts 1c (26%) and 1d (35%) was due primarily to radiographic progression (1c, 10%; 1d, 35%) and withdrawn consent (1c, 10%). Most frequent treatment-related adverse events (AEs) included fatigue (1c, 1d: 26%, 23%), headache (23%, 8%), and increased AST (23%, 0%). Treatment-related serious AEs reported in ≥2 patients were pneumonia (6%, 0%), pyrexia (6%, 0%) and tumor flare (3%, 8%), characterizing either disease progression or pseudoprogression. AEs leading to discontinuation were increased aminotransferases (n=2 [1c] ). No toxic deaths have been reported. CONCLUSIONS: This is the first prospective clinical trial investigating nivolumab in newly diagnosed glioblastoma. Results suggest that the combination of nivolumab with radiotherapy ± temozolomide is feasible and well tolerated, raising no new safety concerns. These data support continued clinical investigation in this population. Updated efficacy results will be presented A dose-escalation clinical study (NCT01470794) using a retroviral replicating vector (RRV), Toca 511, in combination with oral Toca FC (extendedrelease 5-fluorocytosine ) is ongoing to evaluate safety and preliminary efficacy of this investigational therapy in patients with recurrent HGG. Toca 511 (vocimagene amiretrorepvec) encodes a yeast-derived, codon-optimized, heat-stabilized cytosine deaminase (CD) that converts 5-FC to the anticancer drug 5-FU in infected tumors. This virus replicates preferentially in malignant tissue and may have wide application in cancer therapies. When Toca FC is administered, the infected cells are killed by the 5-FU metabolized from 5-FC by the cytosine deaminase protein. In animal tumor models, as infected cancer cells are killed, the diffusible 5-FU also kills neighboring susceptible cells, including myeloid immune suppressor cells that the cancer has attracted to set up an immune-suppressed tumor microenvironment. The killed cancer cells release molecules, such as DAMPs, PAMPs and TLRs that activate antigen presenting cells against released tumor-specific antigens. These tumor antigens are presented to the otherwise intact immune system in the absence of local tumor immune suppression, leading to a robust antitumor immune response that targets tumor specific antigens. In the clinical study presented here, Toca 511 is injected into resection cavity walls at time of tumor resection, and followed with multiple courses of Toca FC. Temporal changes in PBMC populations during treatment were measured. Assays included: subtyping of effector, memory, Treg, and myeloid derived suppressor cell panels by flow cytometry; and specific antitumor activity by assays for tumor reactive peripheral blood monocyte (PBMC). Tumor and blood exome sequencing was performed to assess immunogenic potential of the tumor. Measurement of tumor infiltrating lymphocytes was also performed. A multivariate analysis using immune data and clinical factors will be presented. Clinical data are consistent with the induction of anti-tumor immune responses after Toca-FC administration.
ATIM-18. PHASE I DOSE ESCALATION STUDY OF D2C7-IT ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG)
Annick Desjardins 1 , Dina Randazzo 2 , Vidya Chandramohan 1 ,BACKGROUND: Detailed confirmatory testing and analysis verifies and strengthens the association between clinical outcomes and immune response of HLA-A2+ patients enrolled in a randomized phase 2 trial of ICT-107. METHODS: 77 HLA-A2+ patients, randomized 2:1, received ICT-107 (autologous DCs incubated with 6 synthetic peptide CTL epitopes targeting GBM tumor/stem cell-associated antigens, including the four HLA-A2-restricted antigens HER-2, TRP-2, gp100, and IL-13Rα2) or matching control (un-incubated DC). Multimer testing was performed on a subset of these patients. The pioneering analysis heuristic of fusion metrics used in conjunction with Monte Carlo simulation was used to identify multimer immune responders. P-values between dependent variables and multiple overall survival (OS) or progression-free survival (PFS) metrics was performed using log-rank test and Fisher's exact test. RESULTS: HLA-A2+ patients consistently continued to show evidence of immune response being associated with both OS and PFS. Multimer immune responders independently confirmed the ELISpot immune responder associations between assignment group (p=0.0308), and initial OS and PFS (p=0.0043 and 0.0352, respectively). Combining ELISpot and multimer responders strengthened or maintained associations with all OS and PFS metrics. Notable significant associations were determined when data was stratified by treatment group in both treatment and placebo subgroups, leading to speculation of the possible positive effects of DCs alone. This finding supports changing the placebo in the Phase III study from dendritic cells to PBMCs. CONCLUSIONS: The robust associations identified between OS and PFS with immunologic response, explored using both multimer and ELISpot analysis to determine immune response with fusion metrics in a Monte Carlo setting, provide support for the efficacy of ICT-107 to induce peptide-specific T cell responses in HLA-A2+ patients. BACKGROUND: Recurrence of malignant gliomas following surgery, radiation therapy and adjuvant chemotherapy is nearly universal. The only approved second-line treatment for malignant gliomas is Bevacizumab (Avastin), with estimated 6-month progression-free survival rates of less than 40%. Ultimately, all the GBM patients relapse on Bevacizumab, and no other effective therapies are available. ERC-1671 aims at stimulating the patients' immune system by including patient's glioblastoma tumor as lysates and cells as well as heterologous component generated from three different GBM donors. The NCT01903330 study opened in 2014, and was mandated by the FDA to start with a single -institution, safety lead-in phase before extending to multiple centers. METHODS: Eligible patients were over 18 years of age, had histologically confirmed WHO grade IV malignant glioma and have failed the treatment with radiation and temozolomide. Primary end points are toxicity and 6-month progression-free survival (PFS) while secondary endpoints are safety and overall survival (OS). RESULTS: Data reported as May 1st, 2016 -we have enrolled eight patients -which completed the safety lead-in analysis. Median age was 57, with 2/8 female patients. The average KPS was 80 (70-100). Four patients have stable disease, and their treatment group is not known to the investigator. Four patients had disease progression (at which point the protocol allows for un-blinding), two in the active treatment group and two in the control (BEV) group. No grade 4 or 5 AEs occurred. The grade 3 AEs were intracranial hemorrhage (in the control group), muscle weakness/myalgia (in the control group) and headaches (all three group). The most common AE was headache. CONCLUSION: Based on this safety report, we have now amended the study to allow multi-site enrollment. Updated results will be presented at the SNO meeting.
ATIM-20. A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE ERC-1671 (GLIOVAC) VACCINE IN COMBINATION WITH BEVACIZUMAB (BEV) IN RECURRENT GBM PATIENTS: SAFETY LEAD-IN ANALYSIS

ATIM-21. IMA950 PEPTIDE-BASED VACCINE ADJUVANTED WITH POLY-ICLC IN COMBINATION WITH STANDARD THERAPY IN NEWLY DIAGNOSED HLA-A2 GLIOBLASTOMA PATIENTS: PRELIMINARY RESULTS
Denis Migliorini, Valérie Dutoit, Paul Walker and Pierre-Yves Dietrich; Center of Oncology, Geneva University Hospital, Geneva, Switzerland Phase I/II trial: HLA-A2 positive newly diagnosed GBM patients received after surgery, standard concurrent chemoradiation with temozolomide. In addition patients underwent 6 (before protocol amendment) or 4 (after protocol amendment) vaccinations of IMA-950 with poly ICLC (TLR3 agonist) once a week starting one week after the end of radiation, then 5 vaccinations once a month alternately with the 6 cycles of temozolomide. Primary endpoint was safety, secondary were OS, PFS at 6, 9 months, and immunological endpoints. 19 patients have been enrolled. The first 6 patients received the vaccine intradermally and the adjuvant intramuscularly (IM) in close vicinity and the site varied to stimulate the major draining lymph nodes. The preliminary analysis of vaccine-induced T cell responses didn't show any induction of peptide-specific CD4 or CD8 T cells, leading to design a novel vaccination schedule/formulation. An amendment in the protocol incorporated the following changes: mixing vaccine/adjuvant before injection at one single site (thigh), decreasing the number of vaccinations during the induction phase, testing two different injection routes for the remaining 13 patients (subcutaneously or IM). Clinically, IMA-950 was well tolerated, the most common side effect was local inflammatory reaction at the injection site with mild fever. Some patients experienced cerebral edema, manageable with steroids. Among the 6 first patients, 2 showed disease progression, and median OS was 17.5 months (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . Patients under the amended protocol are still under therapy for 3 of them and 5 others finished the study protocol and are being followed without tumor recurrence. Analysis of vaccine-induced T cell responses in two of the 13 amended patients showed induction of both peptide-specific CD4 and CD8 T cells, suggesting those changes might lead to better immunization. IMA-950 is safe, preliminary mOS seems to be improved. Objective immune responses in two patients were observed.
ATIM-22. PLACEBO CONTROLLED DOUBLE BLIND PHASE IIB/III TRIAL OF AUTOLOGOUS FORMALIN-FIXED TUMOR VACCINE (AFTV-GBM) FOR NEWLY DIAGNOSED GLIOBLASTOMA
Takashi Maruyama; Tokyo Women's Medical University, Department of Neurosurgery, Tokyo, Japan There has been a growing interest in therapeutic modalities based on tumorspecific immune reactions for glioblastoma(GBM). Autologous formalin-fixed tumor vaccine(AFTV) for GBM is an emerging innovative treatment approach, which aims at stimulating patient's own immune system. Based on retrospectively analyzed clinical results of AFTV phase I/II trials, we are conducting double-blind phase IIb/III clinical trial. We have finished two phase I/II trials of AFTV in ACNU era and TMZ era. Newly diagnosed GBM with KPS>60, 16-75yo, more than 80% removal were enrolled for the analysis. Three courses of AFTV were administered after initial treatment radiation without chemotherapy in ACNU era (UMIN0002) and radiation with TMZ in TMZ era as first line therapy(UMIN1426). Median overall survival (mOS) and progression free survival (mPFS) were 19.8 and 7.6 months respectively in UMIN0002. Second AFTV trial resulted in 22,2 and 8,2 months in UMIN1426. There were no significant adverse events of more than grade2. The results of these trials demonstrate the feasibility of AFTV as concomitant treatment of 1stline therapy. We are ongoing multicenter double-blind prospective randomized phase II/ III trial. The study is designed as prospective placebo-control double blind trial. 60 pts were enrolled for phase IIb part. Three course of AFTV were administered before, end and one month after initial treatment of chemo and radiation therapy. OS as primary endpoint and PFS, response rate and QOL are observing. We introduce the rationale and study design of this clinical trial.
ATIM-23. PHASE 1 DOSE ESCALATION STUDY OF CONTROLLED INTRATUMORAL VIRAL DELIVERY OF Ad-RTS-hIL-12 + ORAL VELEDIMEX IN SUBJECTS WITH RECURRENT OR PROGRESSIVE HIGH-GRADE GLIOMA
Francois Lebel; Ziopharm Oncology, Boston, MA, USA BACKGROUND: Ad-RTS-hIL-12 is a novel gene therapy candidate expressing IL-12 under the control of an orally administered activator
